Michael Andrew Postow
Memorial Sloan Kettering Cancer Center · 666 works · 66,286 citations · h-index 90
Top works
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- Nivolumab plus Ipilimumab in Advanced Melanoma
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
- Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
- OncoKB: A Precision Oncology Knowledge Base
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
- Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
- T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
- Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
- Managing Immune Checkpoint-Blocking Antibody Side Effects
- Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
- Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors
- Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).
- Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials